Vanda Pharmaceuticals (VNDA) Corporate presentation summary

Company overview and strategy

• Focuses on innovative therapies with a robust commercial portfolio of five FDA-approved brands and a debt-free balance sheet supporting R&D and commercial growth.

• Strategic priorities include growing and diversifying revenue, advancing late-stage and early-stage pipeline programs, and targeting large markets with unmet needs.

• Imminent regulatory catalysts and commercial expansion are anticipated in 2026.

Product portfolio and pipeline

• Commercial portfolio includes FanaptⓇ, HETLIOZⓇ, PONVORYⓇ, NEREUS™, and BYSANTI™ for psychiatric, sleep, neurological, and gastrointestinal indications.

• Late-stage pipeline features Fanapt LAI, BYSANTI™ for MDD, HETLIOZⓇ for insomnia and jet lag, NEREUS™ for GLP-1-induced vomiting, and imsidolimab for GPP.

• Early-stage pipeline includes candidates for social anxiety, dry eye, cholera, hematologic malignancies, and ASO platform programs.

Recent and upcoming milestones

• FDA approvals for NEREUS™ (motion sickness) and BYSANTI™ (bipolar I disorder, schizophrenia) in early 2026, with commercial launches expected in 2H 2026.

• Phase III results for NEREUS™ (GLP-1-induced vomiting) and BYSANTI™ (MDD) expected in 2026.

• Imsidolimab BLA for GPP accepted with a PDUFA date of December 12, 2026.